Form 4: Cadrenal Therapeutics Insider Sells Shares

Quang Pham, Director and Officer of Cadrenal Therapeutics, reports sale of common stock under a Rule 10b5-1 trading plan.

Summary

• Quang Pham, who holds positions as Director, 10% Owner, and Chairman, CEO, and Interim CFO of Cadrenal Therapeutics, Inc., has reported transactions involving the sale of company common stock.
• These sales occurred on June 25, 2026, and June 26, 2026.
• The transactions were executed under a Rule 10b5-1 trading arrangement, which is designed to satisfy affirmative defense conditions for insider trading.
• On June 25, 2026, 2,127 shares were sold directly at a price of $3.00 per share.
• On June 26, 2026, 9,029 shares were sold directly at a weighted average price of $3.05 per share, with individual sales ranging from $3.00 to $3.18.
• Following these sales, Mr. Pham directly beneficially owns 105,989 shares.
• Additionally, Mr. Pham is noted as indirectly beneficially owning 200,000 shares through The PVBQ Living Trust, where he serves as Trustee and has sole voting and dispositive power. His child is the sole beneficiary of this trust.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to insider selling, even though it was conducted under a pre-planned Rule 10b5-1 arrangement.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and structured approach to stock disposition rather than reactive trading.
• The reporting person, Quang Pham, maintains significant direct and indirect beneficial ownership of the company's stock even after the reported sales.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it represents a reduction in direct ownership by key personnel.
• The total number of shares sold represents a notable portion of the reporting person's holdings.

Risks

• Potential for negative market perception of insider selling, regardless of the structured nature of the transaction.
• The Rule 10b5-1 plan itself could be subject to scrutiny if not properly structured or adhered to.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the range set forth in footnote 2, upon request from the Issuer, any security holder, or the SEC Staff.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to diversify their holdings or manage personal finances without triggering insider trading concerns, but the market often scrutinizes any insider selling.

Related Party Transactions

• The filing details transactions by Quang Pham, who holds multiple executive and director roles, and indirectly through The PVBQ Living Trust where he is the Trustee and his child is the beneficiary. These are disclosed as beneficial ownership changes rather than specific transactions between related parties in the typical sense of a business deal.

Stakeholder Impact

• Shareholders: May interpret insider selling as a signal of reduced confidence, although the Rule 10b5-1 plan mitigates this concern to some extent.
• Employees: May observe insider transactions as part of company performance indicators.
• Management: Demonstrates adherence to regulatory disclosure requirements.

Next Steps

• Continued adherence to the Rule 10b5-1 trading arrangement if applicable.
• Potential future filings of Form 4 for any further changes in beneficial ownership.

Key Dates

Keywords

Cadrenal Therapeutics, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Beneficial Ownership, Quang Pham, SEC Filing, Common Stock, Director, Officer